• 9 June 2011
  • News
  • By

Top 36-40

Span Diagnostics Span Diagnostics clocked an estimated revenue of 92.53 crore for FY 2010-2011, as against 78.98 crore for 2009-10. The company, which has been supplying to India’s national programmes for AIDS and malaria since the past eight years, achieved tender sales worth 28 crore from the Indian government during the past year. Span currently houses three businesses namely, the diagnostic reagent business, the instruments business and exports, and boasts of a joint venture with Japan-based, Nihon Kohden corporation. The company is looking to modernize its plant by investing 12 crore over a period of one-and-half years. The company expects to grow at a rate of 17 to 20 percent in 2011, following which, Span anticipates hitting a growth rate of 25 to 30 percent. This confidence is due to the launch of a number of products by 2012 along with an increase in export sales. Span is looking to achieve a turnover of 1,000 crore by 2020.
Founder and Chairman
Dr Pradip Desai

Business: Provider of diagnostic, instruments & clinical chemistry products
Start-up Year: 1976
Address: 173- B ,New industrial Estate, Udhna, Surat – 394210, Gujarat
Tel: +91-261-2277211
+91-261-2279319, 2665757
Website: www.span.co.in

Revenue: 92.53 crore*

Aventis Pharma Aventis Pharma clocked an estimated sales of 90 crore in FY 2010-11 when compared with 68.34 crore in FY 2009-10. The company has consolidated its position in the growing insulin market with its star product Lantus, which has a market share of 10.24 percent, showing a growth of nearly 30 percent. Other insulin brands including Amaryl and Apidra witnessed a growth of 29 percent and 100 percent respectively. During the FY, the company sold off its entire shareholding in the joint venture company, Chiron Behring Vaccines Private to Novartis Pharma for 100.7 crore. The company reduced the price for its monocomponent insulin, Lantus, by 2.8 percent as per the direction from the National Pharmaceutical Pricing Authority (NPPA) from 2,439.27 for a 10 ml vial of Lantus 100 IU/ml to 2,370.49. The company also has several community service initiatives like the SOS Children’s villages, Childline, the Akansha Foundation, Voluntary Health Association of Goa and the Joy of Giving.
Dr Shailesh Ayyangar

Business: Marketing of biotech products
Start-up Year: 1956
Address: Aventis House, 54/A, Sir Mathuradas, Vasanji Road, Andheri East, Mumbai-400093
Tel: +91-22-28278000    Fax: +91-22-28370939
Website: www.aventispharmaindia.com

Revenue: 90 crore*

Novartis Vaccines In the FY 2010-2011, the vaccine business of Novartis in India clocked 89.65 crore. In India, Novartis and Aventis Pharma had a 51:49 joint venture in Chiron Behring Vaccines, in which the former had marketing rights of the later’s anti-rabies vaccine, Rabipur, in India.
However in December 2010, Aventis Pharma sold off its 49 percent stake in the joint venture to Novartis Vaccines and
Diagnostics (NV&D) for around 100 crore. Novartis Vaccines and Diagnostics division ’s portfolio includes some prominent influenza and meningitis vaccines and travel vaccines.
In the first half of 2010, the division globally completed the distribution of A(H1N1) vaccine.
Now, work has started for developing pre-pandemic vaccines that would provide protection to the global population against possible future pandemics.

Country Head, India
Mr Masood Alam

Business: Healthcare, vaccines and diagnostics
Start-up Year: 2006
Address: Novartis India Limited, Sandoz House, 8th floor, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai - 400 018, India
Tel: +91-22-24958804, 24951074
+91-22-2495 2624 

Revenue: 89.65 crore*

Ajeet Seeds Ajeet Seeds, a producer and processor of hybrid cottonseeds in India, generated a revenue of 87.5 crore in 2010-11. The company received approval from the Genetic Engineering Approval Committee (GEAC), Government of India, for the sale of Bollgard I (Ajeet 33, Ajeet 155, Ajeet 177), Ajeet 901 (HxB), ACH 21 (Arya 21 Bt) and Bollgard II (Ajeet-11, Ajeet 155, Ajeet 33), ACH 177 (Arya 177 BG II, Ajeet 111), ACH 5 (Arya 21 BG II) cotton hybrids in Central, South and North zones in 2006.
The company has developed its own genetic resources of
hybrid seeds in cotton, jowar, bajra, maize, chilli, okra and pigeon pea. The company has established a wide network of 400 distributors, 3,000 dealers and more than 30,000 seed growers all over India. The company is gearing up to launch its indigenous transgenics in okra & cotton that would offer resistance to biotic and abiotic stress.

Mr Sameer Mulay

Business: Research, production, processing and marketing of hybrid seeds
Start-up Year: 1986
Address: Tapadia Terraces, 2nd Floor, Adalat Rd, Aurangabad- 43100
Tel: +91-240-2333933   Fax: +91-240-2333335

Revenue: 87.5 crore*

Haffkine Bio-Pharmaceutical Corporation Haffkine Bio-Pharmaceutical Corporation (HBPCL) is engaged in the manufacture and supply of a wide range of products comprising bacterial and viral vaccines, antisera, toxoids injectables, disinfectants, ointments, injectables, syrups and mixtures. The firm clocked an annual sales revenue of 86 crore for 2010-11 against last year’s 168.98 crore. The firm’s total group turnover, comprising Haffkine Ajintha Pharmaceuticals and Antitoxin and Sera is over 100 crore. The Antitoxin and Sera (ATS) department of HBPCL is located at Pimpri, near Pune, and it is engaged in the manufacture of antiserum against tetanus, diphtheria, gas gangrene, snake and scorpion venoms. The ATS operates on 75 acres of land with a total strength of 400 equines. HBPCL has supplied oral polio vaccines to UNICEF and the Government of India. The company is also planning to build manufacturing facilities complying with the WHO’s GMP standards for DTP/pentavalent vaccine.
Mr P R Sabde

Business: Production and supply of biopharmaceutical products
Start-up Year: 1975
Address: Acharya Donde Marg, Parel, Mumbai - 400012
Tel: +91-22-24129320 Fax: +91-22-24168578
Website: www.vaccinehaffkine.org

Revenue: 86 crore

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email